Menu
Recruiting NCT05388682

Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

— Observational Takayasu Arteritis With Pulmonary Artery Involvement Percutaneous Transluminal Pulmonary Angioplasty PAH Targeted Medication

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Percutaneous transluminal pulmonary angioplasty.
Who it may be relevant to
Registry conditions: Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

Overview

1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement

Detailed description

At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.

Interventions

  • Device Percutaneous transluminal pulmonary angioplasty
    Percutaneous transluminal pulmonary angioplasty

Primary outcome measures

  • all cause death [Time frame: 2014/1/1-2042/12/31]
  • mean pulmonary arterial pressure change [Time frame: 2014/1/1-2042/12/31]
  • pulmonary vascular resistance change [Time frame: 2014/1/1-2042/12/31]
  • 6MWD change [Time frame: 2014/1/1-2042/12/31]
  • peak VO2 change [Time frame: 2014/1/1-2042/12/31]
  • NT-proBNP change [Time frame: 2014/1/1-2042/12/31]
  • RV/LV change [Time frame: 2014/1/1-2042/12/31]
  • CI change [Time frame: 2014/1/1-2042/12/31]

Eligibility criteria

Inclusion criteria

  • patients diagnosed with Takayasu arteries with pulmonary arteries involvement

Exclusion criteria

  • Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sc — Beijing

Identifiers

NCT: NCT05388682 · TAPAI

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗